Author + information
- Received December 21, 2017
- Revision received January 2, 2018
- Accepted January 2, 2018
- Published online March 5, 2018.
- Mehdi H. Shishehbor, DO, MPH, PhDa,∗ (, )
- Michael R. Jaff, DOb,
- Joshua A. Beckman, MDc,
- Sanjay Misra, MDd,
- Peter A. Schneider, MDe,
- Robert Lookstein, MDf,
- Vikram S. Kashyap, MDg,
- Herbert D. Aronow, MD, MPHh,
- W. Schuyler Jones, MDi and
- Christopher J. White, MDj
- aDepartment of Cardiovascular Medicine, Harrington Heart & Vascular Institute, University Hospitals, Cleveland, Ohio
- bDepartment of Vascular Medicine, Newton-Wellesley Hospital, Newton, Massachusetts
- cDepartment of Vascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
- dDepartment of Radiology, Mayo Clinic, Rochester, Minnesota
- eDepartment of Vascular Surgery, Kaiser Permanente Hospital, Oahu, Hawaii
- fDepartment of Radiology, Mount Sinai Health System, New York, New York
- gDepartment of Vascular Surgery, Harrington Heart & Vascular Institute, University Hospitals, Cleveland, Ohio
- hDepartment of Cadiovascular Medicine, Lifespan Cardiovascular Institute, Providence, Rhode Island
- iDepartment of Cardiovascular Medicine, Duke University and Duke Clinical Research Institute, Durham, North Carolina
- jDepartment of Cardiovascular Medicine, Ochsner Medical Center, New Orleans, Louisiana
- ↵∗Address for correspondence:
Dr. Mehdi H. Shishehbor, Case Western Reserve University School of Medicine, University Hospitals, 11100 Euclid Avenue, Lakeside 3rd Floor, Cleveland, Ohio 44106.
On Wednesday, November 1, 2017, the Centers for Medicare and Medicaid Services (CMS) made a public decision to end the transitional pass-through add-on payment for drug-coated balloons beginning January 1, 2018, without creating a new ambulatory payment classification rate for these devices. In this Viewpoint, the authors highlight the disconnect between the CMS’s decision not to create a new ambulatory payment classification category for drug-coated balloons despite demonstrated clinical superiority. The authors believe this decision is more in line with a rigid fee-for-service payment system than a value-based system that encourages quality over quantity, and disadvantages both the elderly and the poor. They call on all who advocate for patients with peripheral artery disease to action, encouraging their engagement on CMS decisions regarding payment.
- Center for Medicare and Medicaid Services
- drug-coated balloons
- pass-through add-on payments
- public health
- value-based system
Dr. Shishehbor has served as a consultant for Abbot Vascular, Medtronic, Boston Scientific, and Philips. Dr. Jaff has served as a noncompensated advisor to Abbott, Boston Scientific, Cordis, and Medtronic; consultant for Micell, Philips/Volcano, Venarum, and Vactronix; and is an equity investor in PQ Bypass, Primacea, Vascular Therapies, Embolitech, and Sano V. Dr. Beckman has served as a consultant for Aralez, AstraZeneca, Bristol-Myers Squibb, Janssen, and Sanofi; has served on the data safety and monitoring board for Bayer; owns equity in EMX and Janacare; and has served on the advisory board for VIVA. Dr. Misra has received research grants from the National Institutes of Health (R01 grant nos. HL098967 and DK 107870) and Boehringer Ingersoll; and has served as the data safety and monitoring board chair for Cordis. Dr. Schneider has received modest royalty from Cook Medical; and has served as the chief medical officer for and is a cofounder of Cagent and Intact Vascular. Dr. Lookstein has served as a consultant for Boston Scientific and Medtronic. Dr. Schuyler Jones has received consulting honoraria from Janssen Pharmaceuticals, Bayer, Bristol-Myers Squibb, Pfizer (all small, <$10k); research grants from the Agency for Healthcare Research and Quality, the Doris Duke Charitable Foundation, Medtronic, and the Patient-Centered Outcomes Research Institute. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received December 21, 2017.
- Revision received January 2, 2018.
- Accepted January 2, 2018.
- 2018 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.